Shanxi C&Y Pharmaceutical Group Co Ltd

Shanxi C&Y Pharmaceutical Group Co Ltd has a high price-to-earnings ratio of 138.69 and a price-to-book ratio of 11.31, indicating that the market is valuing the company at a premium relative to its book value and earnings. The company's liquidity position is assessed as medium, with a current ratio of 0.98, suggesting that it has nearly equal current assets and liabilities. The company's free cash flow of 57.42 million CNY indicates some capacity to fund operations and growth without external financing. The company's profitability is modest, with a return on equity of 8.16% and a return on assets of 1.51%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The operating margin, calculated as operating income of 79.34 million CNY on revenue of 870.79 million CNY, is 9.11%, which is relatively low compared to industry benchmarks. The gross margin of 67.24% is more favorable, indicating that the company is managing production costs effectively. The company's revenue is concentrated in a single geographic market, primarily China, with no disclosed international operations. This concentration increases exposure to local economic and regulatory risks. The company operates as a single business segment, with no material diversification across product lines or therapeutic areas. The company's revenue growth is not explicitly forecasted, but the current financial performance suggests a stable but not rapidly growing business. The capital expenditure of -34.32 million CNY indicates a reduction in investment in physical assets, which may reflect a focus on cost control or a shift toward intangible assets. The company's debt-to-equity ratio of 2.31 is high, indicating a significant reliance on debt financing, which increases financial risk. The company's risk profile includes a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's leverage and potential vulnerability to interest rate fluctuations and refinancing risks. The company has not disclosed any recent equity offerings or dilutive events, and the diluted shares outstanding are equal to the basic shares, indicating no material dilution pressure. The company has not disclosed any recent material events such as earnings calls, regulatory actions, or strategic announcements. The absence of recent filings or transcripts suggests a relatively stable but low-visibility business environment.